Wanebo H J, Rao B, Miyazawa N, Martini N, Middleman M P, Oettgen H F, Beattie E J
J Thorac Cardiovasc Surg. 1976 Sep;72(3):339-50.
Detailed studies of immune reactivity were performed in 154 patients with primary lung cancer, 20 patients with benign thoracic lesions, and 109 healthy persons. Reactions to the 2,4-dinitrochlorobenzene (DNCB) skin test were postive in 73 per cent of patients with lung cancer and all (100 per cent) of the patients with benign disease (p less than 0.05). The incidence of DNCB reactions was 78 per cent for Stage I and II cancers (37 patinets), 73 per cent for resectable Stage III cancer (22 patients), and 66 per cent in patients with unresectable or inoperable Stage III cancer. DNCB reactivity showed a relationship to primary histology. The incidence of DNCB positive reactions was 80 per cent in patients with epidermold carcinoma versus 57 per cent in patients with adenocarcinoma, 64 per cent in patients with oat cell cancer, and 80 per cent in patients with terminal bronchiolar carcinoma. In vitro immune studeis correlated best with stage of disease. These included the absolute lymphocyte count and absolute T cell count and lymphoxyte stimulation witalen A (Com A). These values were in the normal range in patients with Stage I cancer but were significantly depressed in patients with Stage III cancer. Svrvival curves were plotted in patients with Stage III disease according to the responses to three immune parameters: DNCB, absolute lymphocyte count, and PHS stimulation. Although patients with normal reactions generally had better survival rates, PHA responses showed the most significant correlation to survival. These tests support the usefulness of immune testing as an additional parameter of assessing biological risk in patients with primary lung cancer.
对154例原发性肺癌患者、20例胸壁良性病变患者和109名健康人进行了免疫反应的详细研究。肺癌患者中73%对2,4 - 二硝基氯苯（DNCB）皮肤试验呈阳性反应，而良性疾病患者全部（100%）呈阳性反应（p<0.05）。I期和II期癌症患者（37例）中DNCB反应发生率为78%，可切除的III期癌症患者（22例）中为73%，不可切除或无法手术的III期癌症患者中为66%。DNCB反应性与原发性组织学有关。表皮样癌患者中DNCB阳性反应发生率为80%，腺癌患者为57%，燕麦细胞癌患者为64%，终末细支气管癌患者为80%。体外免疫研究与疾病分期相关性最好。这些研究包括绝对淋巴细胞计数、绝对T细胞计数以及淋巴细胞对刀豆蛋白A（Con A）的刺激反应。I期癌症患者这些值在正常范围内，但III期癌症患者明显降低。根据对三种免疫参数（DNCB、绝对淋巴细胞计数和PHA刺激）的反应，绘制了III期疾病患者的生存曲线。虽然反应正常的患者通常生存率较高，但PHA反应与生存的相关性最为显著。这些试验支持免疫检测作为评估原发性肺癌患者生物学风险的一个附加参数的有用性。
